Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 3, Pages 1179-1189Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v22.i3.1179
Keywords
Advanced gastric cancer; Target therapy; Chemotherapy; Strategy; Signal pathway
Categories
Funding
- Technology Innovation Program - Ministry of Trade, Industry and Energy (MI, Korea) [10041653]
- Korea University [K1220401]
- Korea Evaluation Institute of Industrial Technology (KEIT) [10041653] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available